Search hospitals > North Carolina > Pinehurst

FirstHealth of the Carolinas

Claim this profile
Pinehurst, North Carolina 28374
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Endometrial Cancer
Conducts research for Breast Cancer
Conducts research for Endometrial Adenocarcinoma
17 reported clinical trials
2 medical researchers
Photo of FirstHealth of the Carolinas in PinehurstPhoto of FirstHealth of the Carolinas in Pinehurst

Summary

FirstHealth of the Carolinas is a medical facility located in Pinehurst, North Carolina. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Endometrial Cancer, Breast Cancer, Endometrial Adenocarcinoma and other specialties. FirstHealth of the Carolinas is involved with conducting 17 clinical trials across 33 conditions. There are 2 research doctors associated with this hospital, such as Charles S. Kuzma and Michael J. Sundborg, MD.

Area of expertise

1Lung Cancer
FirstHealth of the Carolinas has run 8 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
metastatic
2Non-Small Cell Lung Cancer
FirstHealth of the Carolinas has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
MET positive

Top PIs

Clinical Trials running at FirstHealth of the Carolinas

Lung Cancer
Non-Small Cell Lung Cancer
Endometrial Cancer
Follicular Lymphoma
Colorectal Cancer
Cancer
Parkinson's disease
Endometrial Adenocarcinoma
Non-Hodgkin's Lymphoma
Image of trial facility.

Telisotuzumab Vedotin vs. Docetaxel

for Non-Small Cell Lung Cancer

This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

JNJ-90301900 + Chemoradiation

for Lung Cancer

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Recruiting1 award Phase 23 criteria
Image of trial facility.

Tolododekin Alfa + Cetrelimab

for Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.
Recruiting1 award Phase 15 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at FirstHealth of the Carolinas?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security